RESEARCH HIGHLIGHTS

INNATE LYMPHOID CELLS

On the origin of ILCs



The elusive ILC precursor

an early source of effector cytokines that are typically associated with T helper (T_{μ}) cell subsets. Indeed, they have been subdivided into three main groups according to their production of $T_{H}1$, $T_{H}2$ or $T_{H}17$ cell-associated cytokines. However, ILC lineage relationships are not clear and an important question has remained unanswered - which progenitor cells do ILCs arise from? Now, Constantinides et al. have identified the elusive ILC precursor in mice. This precursor cell is characterized by a high expression level of the transcription factor promyelocytic leukaemia zinc finger (PLZF), and is present in both the fetal liver and the adult bone marrow.

Innate lymphoid cells (ILCs) serve as

PLZF (encoded by Zbtb16) promotes the acquisition of innate effector functions in natural killer T (NKT) cells, a distinct population of innate-like lymphocytes. To study PLZF expression patterns throughout the immune system, the authors generated reporter mice that enabled the detection of cells that currently express, or have previously expressed, Zbtb16. Using these mice, the authors confirmed that NKT cells express PLZF, and that this is most prominent during their early development. Common lymphoid progenitors (CLPs), T cells or B cells did not express PLZF, and they did not seem to express PLZF during their development from haematopoietic stem cells (HSCs). Although mature ILCs do not express PLZF, fate-mapping suggested that ILC1s, ILC2s and ILC3s do express PLZF at some stage during their development from HSCs. However, natural killer (NK) cells and lymphoid tissue-inducer (LTi) cells (currently classified as group 1 and group 3 ILCs, respectively) do not appear to express PLZF at any stage of their development.

This suggested that ILCs may develop from a PLZF-expressing precursor, and the authors identified a rare subset of PLZF^{hi} cells in the fetal liver and bone marrow. These cells did not express markers associated with immune cell lineages (they were LIN-), but were IL-7Ra⁺KIT⁺a4 β 7 integrin^{hi} — a phenotype that has previously been associated with CLP-derived cells that give rise to LTi cells. Notably, the PLZF^{hi} cells expressed other transcription factors associated with ILC development, including GATA3 and RORyt, and they also expressed high levels of TOX, which is necessary for

NK cell and LTi cell development. To study developmental potentials, the authors transferred PLZF^{hi} cells and CLPs into immunodeficient mice. They found that PLZF^{hi} cells gave rise to all ILC lineages, except for LTi cells. Also, although both PLZF^{hi} cells and CLPs generated NK cells, CLPs primarily gave rise to 'classical' NK cells (DX5⁺CD49a⁻NK1.1⁺), whereas PLZF^{hi} cells generated a distinct DX5⁻CD49a⁺NK1.1⁺ subset. Unlike CLPs, PLZF^{hi} cells did not show B cell or T cell developmental potential.

Notably, purified PLZF^{hi} cells also gave rise to ILCs in in vitro culture studies, and these experiments suggested that commitment to individual ILC lineages occurs rapidly during the PLZF^{hi} stage of ILC development. Interestingly, fetal liver-derived PLZF^{hi} cells showed increased ILC3 potential in these studies, compared with their bone marrow-derived counterparts. Finally, the authors showed that PLZF is required for the development of ILC1s and ILC2s, but not for that of ILC3s, despite expression of this transcription factor during ILC3 development.

In summary, the PLZF^{hi} cell seems to represent a precursor that is committed to the development of ILC subsets, with the exception of classical NK cells and LTi cells. This study shows that ILC1s, ILC2s and ILC3s are closely related to, but developmentally distinct from, classical NK and LTi cells.

Yvonne Bordon

ORIGINAL RESEARCH PAPER

Constantinides, M. G. et al. A committed precursor to innate lymphoid cells. *Nature* <u>http://dx.doi.org/10.1038/nature13047</u> (2014) **FURTHER READING** Spits, H. et al. Innate lymphoid cells — a proposal for uniform nomenclature. *Nature Rev. Immunol.* **13**, 145–149 (2013)